NERV vs ALTO

Alto Ingredients, Inc.

(ALTO) offers the better valuation at 35. 6x trailing P/E (13. 4x forward), making it the more compelling value choice. Analysts rate Minerva Neurosciences, Inc. (NERV) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alto Ingredients, Inc.

(ALTO) delivered a total return of -9. 2%, compared to -81. 0% for Minerva Neurosciences, Inc. (NERV). Over 10 years, the gap is even starker: ALTO returned +2. 3% versus NERV's -94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alto Ingredients, Inc.

(ALTO) is the lower-risk stock at 0. 23β versus Minerva Neurosciences, Inc. 's 1. 28β — meaning NERV is approximately 463% more volatile than ALTO relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Alto Ingredients, Inc.

grew EPS 119. 5% year-over-year, compared to -183. 5% for Minerva Neurosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alto Ingredients, Inc.

(ALTO) is the more profitable company, earning 1. 5% net margin versus 0. 0% for Minerva Neurosciences, Inc. — meaning it keeps 1. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALTO leads at 0. 8% versus 0. 0% for NERV. At the gross margin level — before operating expenses — ALTO leads at 3. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ALTO: 75.

4% to $10. 00.

In this comparison, ALTO (0.

3% yield) pays a dividend. NERV does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alto Ingredients, Inc.

(ALTO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23)). Both have compounded well over 10 years (ALTO: +2. 3%, NERV: -94. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NERV (Healthcare) and ALTO (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.